Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

It often mimics the common cold, but RSV can quickly turn into bronchiolitis and pneumonia. “The older you get, the milder ...

As flu season begins, health providers are urging the community to stay up to date on their vaccinations, even if they may be ...

A new study describes the use of artificial intelligence (AI) in designing a new generation of capsids, the structures that ...

Humans, livestock and companion animals benefit from virus-based vaccines and gene therapies, but crops do not. This paradox ...

On Monday 9 September 2024, the Health Directorate within Luxembourg's Ministry of Health and Social Security... }} ...

Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.

Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.

(HealthDay News) — For older adults, respiratory syncytial virus (RSV) vaccination is effective against RSV hospitalization, according to a study published online Sept. 4 in the Journal of the ...

RSV, or respiratory syncytial virus, is a common cause of coughs and colds which can also lead to severe lung infections like pneumonia and infant bronchiolitis – conditions which are highly ...

Respiratory syncytial virus detection was improved with the addition of paired serology testing, standard care swab results, and separate testing of nasopharyngeal and oropharyngeal specimens.